Anika Therapeutics (ANIK) | Stock Overview & Key Data
Anika Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $75.72 on October 21, 2019
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Anika Therapeutics
ANIK
|
221.65M Micro-cap | 0.07% | -2.01% | 1.74% | 52.66% | 56.26% | 34.68% | -44.60% | -63.19% | -70.02% | 116.79% | 39.13% |
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
| 203.22M Micro-cap | -3.74% | -3.74% | -27.46% | -42.78% | -40.46% | -24.29% | -39.77% | -90.89% | -96.46% | -96.46% | -96.46% | |
|
Aurora Cannabis
ACB
|
200.44M Micro-cap | -2.95% | -8.04% | -28.14% | -36.47% | -39.40% | -48.03% | -43.70% | -96.52% | -93.07% | -95.89% | -95.89% |
|
Lifecore Biomedical
LFCR
|
184.39M Micro-cap | -1.44% | 24.77% | 25.63% | -30.33% | -29.07% | -16.20% | -31.88% | -50.83% | -48.63% | -4.73% | -36.20% |
Ownership & Short Interest
Calculate Your Anika Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Anika Therapeutics stock price in Jul 2016 was $52.38, A $1,000.00 lump sum investment in Anika Therapeutics made 9 years ago would be worth approximately $278.92 today, representing a negative return of -72.11%. This translates to an annualized return (CAGR) of -12.09%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ANIK's 52-week high and low?
- In the last 52 weeks, Anika Therapeutics reached a high of $16.24 (on April 20, 2026) and a low of $7.87 (on N/A).
- What is the market cap and P/E ratio for ANIK?
- Curious about Anika Therapeutics's size and valuation? Its market capitalization stands at 221.65M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is 38.33.
- Does ANIK pay dividends? If so, what's the yield?
- As for dividends, Anika Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Anika Therapeutics's main competitors or similar companies to consider before investing?
When looking at Anika Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -51.58% -53.40% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% Organigram Holdings
OGI203.22M Healthcare Drug Manufacturers - Specialty & Generic -24.29% -39.77% Aurora Cannabis
ACB200.44M Healthcare Drug Manufacturers - Specialty & Generic -48.03% -43.70% Lifecore Biomedical
LFCR184.39M Healthcare Drug Manufacturers - Specialty & Generic -16.20% -31.88% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Anika Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Anika Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -6.71%, the Debt to Equity ratio from the most recent quarter is 18.30, and its Gross Profit Margin stands at 62.65%.
- What is the recent revenue and earnings growth for ANIK?
- Looking at Anika Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $113M. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.06%, and quarterly earnings saw a YoY growth of -2,473.26%.
- How much of ANIK stock is held by insiders and institutions?
- Wondering who owns Anika Therapeutics stock? Company insiders (like executives and directors) hold about 5.41% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 92.74%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.